Cargando…
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
Programmed death 1 (PD-1) and its two natural ligands PD-L1 and PD-L2 are responsible for delivering inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. In previous studies, PD-1 was found only expressed on the surface of immune cells, such as T ce...
Autores principales: | Yao, Han, Wang, Huanbin, Li, Chushu, Fang, Jing-Yuan, Xu, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077319/ https://www.ncbi.nlm.nih.gov/pubmed/30105035 http://dx.doi.org/10.3389/fimmu.2018.01774 |
Ejemplares similares
-
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021) -
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018) -
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
por: Hudson, Katie, et al.
Publicado: (2020) -
A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions
por: Yao, Han, et al.
Publicado: (2020) -
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
por: Roy, Dia, et al.
Publicado: (2023)